Hamburg's University Medical Centre Eppendorf (UKE) is one of Germany's major haematology centres, managing severe aplastic anaemia patients requiring combination immunosuppressive therapy plus Eltrombopag. Rompag 50mg provides Hamburg haematology pharmacies with affordable, reliable high-dose Eltrombopag supply at significantly reduced cost versus brand Revolade.
Germany's strong institutional pharmacy procurement processes mean Hamburg hospital pharmacies require full WHO-GMP documentation for generic sourcing. Unnati Pharmax provides complete documentation packages to support German formulary approval processes.
Germany's strong institutional pharmacy procurement processes mean Hamburg hospital pharmacies require full WHO-GMP documentation for generic sourcing. Unnati Pharmax provides complete documentation packages to support German formulary approval processes.
What is the risk of bone marrow fibrosis with long-term Rompag use, and how is it monitored?Bone marrow fibrosis — the development of excess fibrous tissue in the bone marrow — is a recognised but rare risk with prolonged TPO-RA therapy including Eltrombopag. The frequency appears low in clinical practice, but international guidelines recommend periodic bone marrow examination in patients on long-term therapy if blood count abnormalities develop, such as unexpected changes in red cell or white cell counts alongside platelet changes. In clinical practice, haematologists typically perform bone marrow biopsies at significant clinical milestones rather than on a rigid fixed schedule, using the patient's blood count trends as a guide for timing. The risk does not preclude long-term use when Eltrombopag is clinically beneficial, but it should be part of the ongoing
